AAV 유전자 치료약 시장 : 세계 예측(2026-2032년)

The AAV Gene Therapy Drugs Market is projected to grow by USD 41.88 billion at a CAGR of 22.90% by 2032.

AAV Gene Therapy Drugs: Executive Overview

Adeno-associated virus (AAV) gene therapy drugs are medicines that use engineered viral vectors to deliver genetic material to target cells. The field is advancing through improved vector design, manufacturing, clinical development, and regulatory science. Its principal opportunities lie in treating serious diseases with limited therapeutic options, while its principal constraints include immune responses, tissue targeting, durability, manufacturing complexity, and high evidentiary requirements.

How Vector Science and Delivery Are Reshaping the Field

The landscape is shifting from proof-of-concept therapies toward more precise control of biodistribution, transgene expression, and repeat dosing. Developers are investigating capsid engineering, tissue-specific promoters, dose optimization, alternative administration routes, and methods to reduce pre-existing immunity. Manufacturing is also evolving through scalable upstream and downstream processes, improved analytics, and greater attention to product comparability when processes change.

Artificial Intelligence Accelerates Discovery, Development, and Oversight

Artificial intelligence is being applied to identify capsid candidates, model protein structure, predict tissue tropism, analyze clinical and manufacturing data, and improve trial design. These tools can help prioritize experiments and detect quality trends earlier, but they do not remove the need for laboratory validation, transparent datasets, reproducible methods, and regulatory review. The most durable impact is likely to come from combining machine learning with curated biological data, robust process controls, and expert interpretation.

Regional Dynamics: Regulation, Manufacturing, and Clinical Capability

North America has strong capabilities in translational research, biotechnology manufacturing, and advanced clinical development. Europe emphasizes harmonized regulatory expectations, specialized academic centers, and cross-border evidence generation. Asia-Pacific combines expanding research infrastructure with substantial patient populations and growing manufacturing capacity. Latin America is developing clinical and regulatory capabilities while facing access and infrastructure constraints. The Middle East is investing selectively in advanced healthcare and biotechnology platforms, whereas Africa remains focused on building research, diagnostic, manufacturing, and referral capacity needed for complex genetic medicines.

Group Perspectives: Cooperation and Policy Alignment

ASEAN countries are relevant to regional trial networks, health-system readiness, and technology transfer, although regulatory and infrastructure maturity varies. BRICS members span major research, manufacturing, and patient ecosystems, with collaboration shaped by differing rules and industrial policies. The European Union benefits from coordinated scientific and regulatory frameworks, while the G7 provides influential standards, research capacity, and financing channels. GCC states are strengthening specialized healthcare and biotechnology capabilities. NATO members collectively include many advanced biomedical ecosystems, but defense alignment does not replace national regulation, reimbursement policy, or clinical governance.

Country Insights Across Research, Regulation, and Access

The United States and Canada combine advanced clinical research, specialized manufacturing, and established regulatory expertise. The United Kingdom, France, Germany, Italy, and Spain contribute through academic medicine, European regulatory coordination, and national health-system assessment. China is expanding domestic innovation, clinical infrastructure, and manufacturing capabilities, while Japan and South Korea bring strong translational science and advanced biomanufacturing. Australia supports gene-therapy research through specialized institutions and a structured regulatory environment. India is strengthening biotechnology, clinical research, and manufacturing capacity. Brazil and Mexico are important Latin American centers for specialist care and clinical development, while Russia retains scientific and healthcare capabilities subject to regulatory, funding, and international collaboration conditions.

Priorities for Leaders Building Durable AAV Gene Therapy Programs

Industry leaders should prioritize clinically meaningful endpoints, transparent natural-history evidence, and early engagement with regulators and payers. Manufacturing strategies should establish scalable processes, validated analytical methods, supply resilience, and clear comparability plans before pivotal development. Programs should also assess pre-existing immunity, liver and other organ risks, long-term follow-up, and the feasibility of patient identification and treatment delivery. Responsible use of artificial intelligence requires documented validation, human oversight, cybersecurity, and controls against biased or irreproducible outputs. Partnerships with specialist hospitals, public agencies, and patient organizations can improve referral, consent, monitoring, and equitable access.

Methodology: Evidence-Based Assessment of the AAV Drug Landscape

This executive summary uses a structured qualitative assessment of AAV gene therapy drugs across scientific, clinical, manufacturing, regulatory, health-system, and geographic dimensions. Insights are derived from publicly available regulatory materials, peer-reviewed research, clinical-trial documentation, technical literature, and established healthcare-policy sources. Regional, group, and country observations are presented as contextual comparisons rather than numerical rankings. The assessment excludes market estimates, market shares, forecasts, and unsupported claims, and emphasizes patterns that can be corroborated through documented evidence.

Conclusion: Advancing AAV Therapies Through Precision and Discipline

AAV gene therapy drugs are progressing through a period of technical refinement and institutional learning. Future success will depend less on vector novelty alone than on integrated execution across targeting, safety, durability, manufacturing, evidence generation, regulation, and patient access. Organizations that pair rigorous translational science with resilient production, responsible artificial intelligence, and coordinated health-system planning will be better positioned to convert promising genetic approaches into dependable clinical care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. AAV Gene Therapy Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Hematology
  • 7.2.1. Beta Thalassemia
  • 7.2.2. Hemophilia A
  • 7.2.3. Hemophilia B
• 7.3. Metabolic
  • 7.3.1. Fabry Disease
  • 7.3.2. Gaucher Disease
• 7.4. Musculoskeletal
  • 7.4.1. Becker Muscular Dystrophy
  • 7.4.2. Duchenne Muscular Dystrophy
• 7.5. Neurology
  • 7.5.1. Alzheimer's Disease
  • 7.5.2. Parkinson's Disease
  • 7.5.3. Spinal Muscular Atrophy
• 7.6. Ophthalmology
  • 7.6.1. Age Related Macular Degeneration
  • 7.6.2. Leber's Congenital Amaurosis
  • 7.6.3. Retinal Dystrophy

8. AAV Gene Therapy Drugs Market, by Vector Type

• 8.1. Introduction
• 8.2. AAV2
• 8.3. AAV5
• 8.4. AAV8
• 8.5. AAV9

9. AAV Gene Therapy Drugs Market, by End-User

• 9.1. Introduction
• 9.2. Contract Manufacturing Organizations
• 9.3. Hospitals
• 9.4. Research Institutes
• 9.5. Specialty Clinics

10. AAV Gene Therapy Drugs Market, by Administration Route

• 10.1. Introduction
• 10.2. Intramuscular
• 10.3. Intrathecal
• 10.4. Intravenous
• 10.5. Subretinal

11. AAV Gene Therapy Drugs Market, by Therapy Stage

• 11.1. Introduction
• 11.2. Approved
• 11.3. Phase I
• 11.4. Phase II
• 11.5. Phase III
• 11.6. Preclinical

12. AAV Gene Therapy Drugs Market, by Modality

• 12.1. Introduction
• 12.2. Combination Therapy
• 12.3. Monotherapy

13. AAV Gene Therapy Drugs Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. AAV Gene Therapy Drugs Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. AAV Gene Therapy Drugs Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. 4D Molecular Therapeutics
• 17.2. Abeona Therapeutics Inc.
• 17.3. Adaptimmune Therapeutics PLC
• 17.4. Adverum Biotechnologies Inc.
• 17.5. Amgen Inc.
• 17.6. Astellas Pharma Inc.
• 17.7. BioMarin Pharmaceutical Inc.
• 17.8. bluebird bio Inc.
• 17.9. Capsida Biotherapeutics
• 17.10. CRISPR Therapeutics AG
• 17.11. CSL Behring LLC
• 17.12. F. Hoffmann-La Roche Ltd.
• 17.13. Krystal Biotech Inc.
• 17.14. MeiraGTx
• 17.15. Novartis AG
• 17.16. Pfizer Inc.
• 17.17. REGENXBIO Inc.
• 17.18. Sarepta Therapeutics Inc.
• 17.19. Spark Therapeutics Inc.
• 17.20. Takeda Pharmaceutical Company Limited
• 17.21. uniQure N.V.
• 17.22. Vertex Pharmaceuticals Incorporated
• 17.23. Voyager Therapeutics Inc.

18. Key Experts